Barclays
PGEN icon

Barclays’s Precigen PGEN Stock Holding History

Barclays’s Portfolio PGEN Stock Details PGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.31M Buy
931,368
+439,672
+89% +$1.9M ﹤0.01% 1804
2026
Q1 		$1.9M Sell
491,696
-373,682
-43% -$1.53M ﹤0.01% 2382
2025
Q4 		$3.62M Buy
865,378
+309,522
+56% +$1.2M ﹤0.01% 2474
2025
Q3 		$1.83M Buy
555,856
+249,438
+81% +$704K ﹤0.01% 2953
2025
Q2 		$435K Buy
306,418
+126,583
+70% +$180K ﹤0.01% 3831
2025
Q1 		$268K Sell
179,835
-63,064
-26% -$99.3K ﹤0.01% 3890
2024
Q4 		$272K Buy
242,899
+53,546
+28% +$45.7K ﹤0.01% 4157
2024
Q3 		$179K Buy
189,353
+124,141
+190% +$157K ﹤0.01% 4355
2024
Q2 		$103K Sell
65,212
-48,084
-42% -$69.8K ﹤0.01% 3890
2024
Q1 		$164K Sell
113,296
-93,244
-45% -$134K ﹤0.01% 4223
2023
Q4 		$277K Buy
206,540
+161,448
+358% +$190K ﹤0.01% 4265
2023
Q3 		$64K Sell
45,092
-3,764
-8% -$5.33K ﹤0.01% 3757
2023
Q2 		$56.2K Sell
48,856
-34,635
-41% -$40.9K ﹤0.01% 3787
2023
Q1 		$88.5K Buy
83,491
+34,484
+70% +$49.7K ﹤0.01% 4246
2022
Q4 		$74.5K Buy
49,007
+22,823
+87% +$39.3K ﹤0.01% 4392
2022
Q3 		$55K Buy
26,184
+21,114
+416% +$44.5K ﹤0.01% 3753
2022
Q2 		$7K Buy
5,070
+5,065
+101,300% +$7.51K ﹤0.01% 4722
2022
Q1 		$0 Buy
+5
New +$12 ﹤0.01% 5462
2020
Q1 		– Sell
-293,770
Closed -$1.61M – 6389
2019
Q4 		$1.61M Buy
293,770
+9,183
+3% +$51.7K ﹤0.01% 3217
2019
Q3 		$1.63M Sell
284,587
-48,446
-15% -$329K ﹤0.01% 3118
2019
Q2 		$2.55M Buy
333,033
+113,550
+52% +$611K ﹤0.01% 2631
2019
Q1 		$1.15M Sell
219,483
-291,921
-57% -$2.02M ﹤0.01% 3253
2018
Q4 		$3.35M Sell
511,404
-331,955
-39% -$3.72M ﹤0.01% 1907
2018
Q3 		$14.5M Buy
843,359
+43,635
+5% +$649K 0.01% 1034
2018
Q2 		$11.1M Buy
799,724
+124,241
+18% +$2.1M 0.01% 1145
2018
Q1 		$10.4M Sell
675,483
-16,173
-2% -$231K 0.01% 1161
2017
Q4 		$7.97M Buy
691,656
+676,513
+4,467% +$10.1M 0.01% 1318
2017
Q3 		$287K Buy
15,143
+14,958
+8,085% +$308K ﹤0.01% 4121
2017
Q2 		$4K Sell
185
-52,694
-100% -$1.16M ﹤0.01% 6302
2017
Q1 		$1.05M Sell
52,879
-29,733
-36% -$664K ﹤0.01% 2688
2016
Q4 		$1.99M Buy
82,612
+74,584
+929% +$2.08M ﹤0.01% 2126
2016
Q3 		$224K Buy
8,028
+7,796
+3,360% +$206K ﹤0.01% 3881
2016
Q2 		$6K Sell
232
-4,930
-96% -$140K ﹤0.01% 5708
2016
Q1 		$169K Sell
5,162
-16,397
-76% -$516K ﹤0.01% 3955
2015
Q4 		$642K Sell
21,559
-31,542
-59% -$1.06M ﹤0.01% 2998
2015
Q3 		$1.63M Buy
53,101
+52,129
+5,363% +$2.54M ﹤0.01% 2296
2015
Q2 		$46K Sell
972
-774
-44% -$32.6K ﹤0.01% 5197
2015
Q1 		$75K Sell
1,746
-138,321
-99% -$4.97M ﹤0.01% 5018
2014
Q4 		$3.61M Buy
140,067
+136,139
+3,466% +$2.99M ﹤0.01% 1982
2014
Q3 		$68K Sell
3,928
-2,314
-37% -$47.2K ﹤0.01% 5629
2014
Q2 		$150K Buy
6,242
+3,516
+129% +$71.3K ﹤0.01% 5106
2014
Q1 		$68K Buy
2,726
+410
+18% +$11.3K ﹤0.01% 5746
2013
Q4 		$52K Buy
2,316
+989
+75% +$20K ﹤0.01% 6155
2013
Q3 		$29K Buy
+1,327
New +$30.6K ﹤0.01% 6359

Other funds holding PGEN

PCM
Patient Capital Management Baltimore, Maryland $3.05B AUM 42.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Barclays's PGEN Position: Q2 2026 in Review

Barclays increased its Precigen (PGEN) stake by 89% in Q2 2026, buying an estimated $1.9M and bringing the position to 931,368 shares worth $5.31M. The position accounts for ﹤0.01% of the portfolio, ranked #1804.

Barclays first reported a position in PGEN in Q3 2013 and has held it in 44 quarters since. The position peaked at $14.5M in Q3 2018. 211 funds tracked by Wall St. Rank hold PGEN as of Q2 2026.

  • Barclays held 931,368 shares of Precigen worth $5.31M as of Q2 2026.
  • Barclays bought 439,672 Precigen shares in Q2 2026, an estimated $1.9M.
  • Precigen made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1804 holding.
  • Barclays first reported a position in Precigen in Q3 2013 and has held it in 44 quarters since.
  • Barclays's Precigen position peaked at $14.5M in Q3 2018.
  • 211 funds tracked by Wall St. Rank held Precigen as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.